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Abstract
Background: Diabetic foot infections are common, serious, and diverse. There is uncertainty about optimal
antibiotic treatment, and probably substantial variation in practice. Our aim was to document whether this is the
case: A finding that would raise questions about the comparative cost-effectiveness of different regimens and also
open the possibility of examining costs and outcomes to determine which should be preferred.
Methods: We used the Veterans Health Administration (VA) Diabetes Epidemiology Cohorts (DEpiC) database to
conduct a retrospective observational study of hospitalized patients with diabetic foot infections. DEpiC contains
computerized VA and Medicare patient-level data for VA patients with diabetes since 1998, including
demographics, ICD-9-CM diagnostic codes, antibiotics prescribed, and VA facility. We identified all patients with
ICD-9-CM codes for cellulitis/abscess of the foot and then sub-grouped them according to whether they had
cellulitis/abscess plus codes for gangrene, osteomyelitis, skin ulcer, or none of these. For each facility, we
determined: 1) The proportion of patients treated with an antibiotic and the initial route of administration; 2) The
first antibiotic regimen prescribed for each patient, defined as treatment with the same antibiotic, or combination
of antibiotics, for at least 5 continuous days; and 3) The antibacterial spectrum of the first regimen.
Results: We identified 3,792 patients with cellulitis/abscess of the foot either alone (16.4%), or with ulcer (32.6%),
osteomyelitis (19.0%) or gangrene (32.0%). Antibiotics were prescribed for 98.9%. At least 5 continuous days of
treatment with an unchanged regimen of one or more antibiotics was prescribed for 59.3%. The means and
(ranges) across facilities of the three most common regimens were: 16.4%, (22.8%); 15.7%, (36.1%); and 10.8%,
(50.5%). The range of variation across facilities proved substantially greater than that across the different categories
of foot infection. We found similar variation in the spectrum of the antibiotic regimen.
Conclusions: The large variations in regimen appear to reflect differences in facility practice styles rather than case
mix. It is unlikely that all regimens are equally cost-effective. Our methods make possible evaluation of many
regimens across many facilities, and can be applied in further studies to determine which antibiotic regimens
should be preferred.
Background
Foot infections in diabetic patients are among the most
frequent precipitating causes of hospitalization and
amputation[1-3]. They may result from many different
microbial species, either singly or in combination, and
response to treatment may be poor, particularly when
vascular disease is also present, as is common in
diabetes. The Infectious Diseases Society of America has
issued a guideline in an effort to standardize and
improve care[4,5]. Uncertainty remains, however,
regarding the optimal antibiotic regimens for the various
types of infection that may occur[6-8]. Lack of consen-
sus about optimal treatment means that there is sub-
stantial latitude in the choice of antibiotics for diabetic
foot infections, with the likely result that there will be
substantial variation in practice. The aim of this study
was to determine whether this is the case. To the degree
that such variation can be documented, it would raise
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questions about the comparative cost-effectiveness of
different regimens and also open the possibility of exam-
ining costs and outcomes in order to determine which
regimens should be preferred.
The Veterans Health Administration is the largest
integrated health care system in the country and
includes 147 hospitals. It has an excellent computerized
patient record system, which contains patient demo-
graphics, diagnoses, diagnostic studies, treatments
received and patient outcomes. With this information it
is possible to examine the antibiotic regimens of large
numbers of diabetic patients with foot infections and
the degree to which practice patterns vary across
facilities.
In previous work, we reported the construction of a
classification system for diabetic foot infections that is
expressly designed for use with computerized medical
data. We applied it to a database that contains all dia-
betic patients in the Veterans Health Administration
(VA), and found support for our classification in its cor-
relation with patient characteristics, treatments received,
and outcomes, including rehospitalization, amputation,
transition to long-term care, and death [9].
In the present study, we have used our classification
system to identify diabetic patients with serious active
foot infections, as defined by hospitalization with iso-
lated cellulitis or cellulitis accompanied by gangrene,
osteomyelitis, or ulcer. We have also developed and
applied methods for assessing variation in complex
multi-drug antibiotic regimens to examine how the
treatment of these patients varies across hospitals in the
VA healthcare system. We have found that there is large
variation in treatment across facilities and that there is
more variation across facilities than across different
types of infection. This suggests that practice styles play
a larger role in the choice of regimen than does case
mix.
Methods
The Study Population and Source Data
This study was approved by the Institutional Review
Board (IRB) of the Edith Nourse Rogers VA Medical
Center in Bedford, Massachusetts. It was conducted in
the population of hospitalized veteran diabetic patients
receiving care from the Veterans Health Administration
(VA) in fiscal year (FY) 2006. We used the national VA
Diabetes Epidemiology Cohorts (DEpiC), a linked, com-
puterized research database that serves as a registry of
virtually all VA patients with diabetes. Patients are
included in DepiC on the basis of having two of the fol-
lowing ICD-9CM codes within a 24-month period: 250.
xx, 357.2, 362.0, or 366.41. It contains patient-level data
on medical visits, pharmacy and laboratory data, with
diagnoses and procedures for VA and non-VA care
(from Medicare claims data)[10,11]. For this study, we
used ICD-9CM diagnosis and procedure codes from VA
inpatient files along with inpatient antibiotic prescrip-
tions. The records for inpatient antibiotics include
generic name of the medication and dose, with separate
entries for each date that the antibiotic was adminis-
tered. For this analysis, we did not include antibiotics
prescribed on an outpatient basis or any non-VA
hospitalizations.
Identification and classification of diabetic foot infections
Our methods for the identification and classification of
diabetic foot infections have been described elsewhere
[9]. In brief, we used ICD-9-CM codes to identify dia-
betic patients who had any of the various codes that
indicate foot infection during a VA hospitalization in
FY2006. Some patients proved to have coexisting foot
infections of different types. We reasoned that the most
severe of these infections would determine the strength
of association with such things as response to treatment,
length of hospital stay, amputation rate, and other
outcomes. Therefore, we ranked the infections in a
presumptive order of severity and assigned the infection
to the most severe category for which they had an
ICD-9-CM code. Our presumptive order was Gangrene
> Osteomyelitis > Foot ulcer > Cellulitis/abscess of foot
> Cellulitis/abscess of toe > Paronychia. In the present
study, we first identified all patients with ICD-9-CM
codes for cellulitis/abscess of the foot and then sub-
grouped them according to whether they had cellulitis/
abscess plus codes for gangrene, osteomyelitis, skin
ulcer, or none of these. If cellulitis/abscess was accom-
panied by codes for more than one of the foregoing 3
conditions, then we chose the one that was more severe.
Figure 1 is a flow diagram that shows the genesis of the
study population. The ICD-9-CM codes that we used
are given in the appendix.
We assumed that patients were under treatment for
diabetic foot infection while in the hospital if, during
that hospitalization, they were assigned an ICD-9-CM
code for cellulitis of the foot.
Antibiotic treatment of patients with diabetic foot
infections
First, we eliminated from consideration antibiotics that
would not be used in the treatment of diabetic foot
infections. These included antivirals, antifungals, and
antiparasitics, as well as select antibacterial agents,
including antituberculosis agents other than rifampin,
agents used only for urinary tract infections (e.g. nitro-
furantoin, methenamine), and antibacterial agents with a
very narrow spectrum of activity, such as penicillin
G and spectinomycin. We then evaluated antibiotic
prescribing in the following ways:
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1. The proportion of patients treated with an antibio-
tic and the initial route of administration on the first
day that any antibiotic was given.
2. The first antibiotic regimen prescribed for each
patient, defined as treatment with the same antibiotic,
or combination of antibiotics, for at least 5 continuous
days. This may not be the same as the antibiotics that
were given on the first day. We chose this duration of
time to allow for consultation about the choice of anti-
biotics, integration of microbiological information, and
observation of clinical response. Also, duration sufficient
to observe clinical response is a necessary requirement
for future studies to determine which regimens should
be preferred.
3. The antibacterial spectrum of the first antibiotic regi-
men prescribed for each patient. We used the Medical
Letter on Drugs and Therapeutics Handbook of Antimi-
crobial Therapy to determine whether an antibiotic was a
recommended agent for: gram-positive organisms other
than S. aureus; methicillin sensitive S. aureus; methicillin
resistant S. aureus; Ps. aeruginosa; and B. fragilis[12].
(We considered regimens to target B. fragilis only if they
contained either clindamycin or metronidazole.) In addi-
tion, we divided the gram-negative spectrum against
Figure 1 Study population.
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organisms other than Ps. aeruginosa into broad and nar-
row. We classified ampicillin, amoxicillin, and second
generation cephalosporins as narrow spectrum agents
and the remaining agents as broad spectrum.
Statistical analyses
We used a Bayesian model and an adjusted likelihood
method[13] to estimate values of true rates by facilities.
This method shrinks the estimate toward the overall
mean, considers the strength of the information about a
hospital’s true rate relative to the variation across hospi-
tals, and allows estimates from hospitals with small sam-
ple sizes[14].
Estimates of the true mean rates incorporate informa-
tion from a facility’s observed rate with information
from the distribution of rates of all facilities. If the infor-
mation from a facility is weak, i.e., the sample size at the
facility is small, the estimate of the true rate will be
pulled closely toward the overall rate; when the informa-
tion is strong, the estimate of the true rate will be closer
to the facility’s observed rate. Although there is statisti-
cal error associated with our estimates of true rates, the
Bayesian model lets us focus on the parameters of inter-
est rather than focusing on observed rates where ran-
dom variation is expected.
We characterized the variation in true rates in three
ways: range, interquartile range, and range/median. The
range is the difference between the lowest and highest
values. The interquartile range is the difference between
the lowest and highest values in the middle two quar-
tiles of the data. The range/median is similar to the
coefficient of variation (standard deviation divided by
the mean) in that large values mean that the range of
true rates is large relative to the typical value of the true
rates. A large value could indicate one or more extreme
outliers or true rates with large variation but without
extreme outliers.
Results
Study population
There were nearly 1.2 million veteran VA patients with
diabetes in DEpiC in FY 2006. We identified 3,792 who
had a VA hospitalization in that year with ICD-9-CM
codes classifiable into one of our four categories of cel-
lulitis. Of these, 3751 (98.9%) were treated with one or
more antibiotics and 2248 (59.3%) received at least 5
continuous days with the same antibiotic(s). Table 1
shows the characteristics of our patient population over-
all and of the subpopulations of patients with Cellulitis-
Gangrene, Cellulitis-Osteomyelitis, Cellulitis-Ulcer, and
Cellulitis-Only. Overall, more than 98% were men, the
average age was 65, and 63% were white. There was
some variation in these characteristics across the differ-
ent categories of cellulitis. Patients with gangrene were
slightly older (average age 67) and there were fewer
white patients among those with osteomyelitis (54.4%).
Proportion of patients treated with antibiotics and routes
of administration
In this analysis we included all the antibiotics that were
prescribed on the first day that any antibiotic was given.
Of 3,792 patients overall who had cellulitis, 3,751
(98.9%) were treated, 79.8% parenterally, 11.5% orally,
7.6% both parenterally and orally, and 1.1% neither (i.e.
no antibiotic). The greatest difference in initial route of
administration was in the Cellulitis-Only group, in
which purely parenteral antibiotics were used least often
(74.6%), and purely oral antibiotics most often (15.4%),
compared to the other groups (Figure 2).
First antibiotic regimen prescribed to patients with foot
cellulitis
Of the 3,792 total patients with any cellulitis, 1544
(40.7%) never received a course of antibiotics that met
our definition of an antibiotic regimen. This reflects the
Table 1 Demographics of patients with different categories of cellulitis
Total Cellulitis and
Gangrene
Cellulitis and
Osteomyelitis
Cellulitis and
Ulcer
Cellulitis Only
N % N % N % N % N %
3,792 100 1,213 32.0 720 19.0 1,237 32.6 622 16.4
Sex
Male 3,748 98.8 1,203 99.2 713 99.0 1,220 98.6 612 98.4
Age in 2006
Mean (SD)
65 (10.6) 67 (10.3) 63 (10.4) 64 (10.5) 64 (11.2)
Race
White 2,371 62.5 757 62.4 392 54.4 817 66.0 405 65.1
African American 440 11.6 168 13.8 84 11.7 119 9.6 69 11.1
Other 245 6.5 94 7.8 56 7.8 60 4.9 35 5.6
Unknown 736 19.4 194 16.0 188 26.1 241 19.5 113 18.2
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fact that either a single day’s missed dose or 1-4 days of
an additional antibiotic would disqualify an antibiotic
regimen from consideration.
The percentage of patients with no first regimen varied
across our four categories of cellulitis. Seventy-four per-
cent of patients with Cellulitis-Gangrene received a first
regimen, compared to 70% for Cellulitis-Osteomyelitis,
52% for Cellulitis-Ulcer, and 33% for Cellulitis-Only. Since
we know that at least 98% of patients in each group were
given antibiotics, these declining percentages reveal a cor-
responding decrease in the proportion of patients who
received an unmodified course of treatment for 5 days or
more. A total of 199 different antibiotic regimens were
used. This large number reflects the many possible combi-
nations of the 52 different antibiotics that were prescribed.
Table 2 shows the 17 regimens that were used in
more than 1% of patients. The columns labeled
“Observed Proportion” show the mean percentage of
patients receiving each regimen overall, and then sepa-
rately for each category of cellulitis. In all instances
treatment was most often partitioned across the regi-
mens of piperacillin/tazobactam, piperacillin/tazobactam
plus vancomycin, and ampicillin/sulbactam.
The rows of the table reveal that there are not large
differences in the choice of each regimen across the
categories of cellulitis. The greatest difference is 11.4%
for Piperacillin-tazobactam (high 20.1% for Cellulitis-
Gangrene, low 8.7% for Cellulitis-Only). In general, the
largest differences in frequency of use across the differ-
ent categories of cellulitis occur with Cellulitis-Only, in
which a substantially smaller proportion of patients
received piperacillin-tazobactam and piperacillin-tazo-
bactam plus vancomycin.
The range of use for each regimen across facilities
within each category of cellulitis is at least equal to, and
usually substantially greater than, the range of observed
proportions across the different types of cellulitis (i.e.
the range of variation across facilities is generally greater
than that across the different categories of cellulitis).
Figure 3 is a graphical representation of the first column
of Table 2, and displays the findings for the study popula-
tion as a whole. It shows the interquartile range in addi-
tion to the full range. The large difference between these
indicates that divergent prescribing patterns in a small
number of facilities accounts for a large part of the full
range of variation that we have observed. Calculation of
the range to median ratio, an additional measure of varia-
tion (data not shown), highlights the antibiotic regimens
for which variation in use is particularly great in relation
to the median. It specifically identifies ticarcillin/clavula-
nate, ertapenem, and ciprofloxacin/clindamycin as highly
variable. Though the latter two are given to less than 2%
of patients overall, the range of usage is very large by com-
parison to the median.
Figure 2 Proportion of patients receiving antibiotics and routes of administration.
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Table 2 Proportion of patients receiving each of the 17 most common first antibiotic regimens
Overall Cellulitis and
Gangrene
Cellulitis and
Osteomyelitis
Cellulitis and
Ulcer
Cellulitis Only
(n = 2248) (n = 894) (n = 503) (n = 644) (n = 207)
Observed Proportion (Range*) %
Piperacillin-tazobactam 16.4 (22.8) 20.1 (23.9) 14.7 (24.2) 14.9 (14.2) 8.7 (11.5)
Piperacillin-tazobactam, Vancomycin 15.7 (36.1) 16.1 (33.9) 18.1 (58.3) 15.4 (21.8) 9.7 (11.3)
Ampicillin-sulbactam 10.8 (50.5) 11.3 (42.5) 10.7 (48.8) 9.5 (30.7) 12.6 (21.4)
Vancomycin 6.9 (13.5) 6.2 (6.1) 9.1 (21.1) 5.7 (7.0) 7.7 (13.8)
Cefazolin 4.2 (12.6) 3.4 (9.2) 3.2 (19.7) 5.6 (14.4) 6.3 (12.1)
Amoxicillin-clavulanate§ 2.0 (3.3) 1.5 (4.1) 0.6 (10.9) 3.7 (7.3) 2.4 ( - )
Ticarcillin-clavulanate 2.0 (48.6) 1.9 (41.6) 1.6 (40.6) 2.5 (43.1) 1.9 ( - )
Cephalexin§ 1.6 (7.3) 0.8 (4.6) 0.8 (26.2) 2.2 (10.1) 4.8 (12.7)
Ertapenem 1.4 (14.9) 1.0 (11.5) 2.6 (19.9) 0.5 (12.1) 1.0 ( - )
Ciprofloxacin§ 1.3 (2.5) 1.2 (6.1) 1.4 (6.1) 1.6 (7.9) 0.5 ( - )
Ampicillin-sulbactam, vancomycin 1.2 (3.0) 1.2 (2.7) 1.4 (17.4) 1.1 (3.7) 1.0 ( - )
Imipenem 1.2 (4.3) 2.1 (11.5) 0.8 (24.9) 0.3 ( - ) 1.0 ( - )
Ceftriaxone 1.2 (3.8) 0.8 (3.7) 1.4 (6.2) 1.6 (6.9) 1.0 ( - )
Ciprofloxacin, clindamycin 1.1 (12.7) 1.5 (21.1) 0.6 (15.6) 0.8 (2.9) 1.4 ( - )
Clindamycin 1.1 (3.6) 1.1 (7.2) 0.8 (9.7) 0.8 (10.8) 2.4 ( - )
Gatifloxacin§ 1.1 (4.1) 0.4 (8.1) 1.2 (3.9) 1.9 (23.7) 1.0 ( - )
Nafcillin 1.1 (2.8) 0.6 (6.5) 1.4 (7.9) 1.1 (25.1) 2.4 ( - )
* Statistic uses shrunken hospital rates (see methods)
§ Given orally
( - ) No range
0 0.1 0.2 0.3 0.4 0.5 0.6
piperacillin tazobactam(INJ)
piperacillin tazobactam(INJ) vancomycin(INJ)
ampicillin sulbactam(INJ)
vancomycin(INJ)
cefazolin(INJ)
amoxicillin clavulanate(Oral)
ticarcillin clavulanate(INJ)
cephalexin(Oral)
ertapenem(INJ)
ciprofloxacin(Oral)
ampicillin sulbactam(INJ) vancomycin(INJ)
imipenem(INJ)
ceftriaxone(INJ)
ciprofloxacin(INJ) clindamycin(INJ)
clindamycin(INJ)
gatifloxacin(Oral)
nafcillin(INJ)
         Mean 
         Range 
         Interquartile range with median 
Figure 3 Proportion of patients receiving each of the 17 most common first antibiotic regimens.
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Antibacterial spectrum of first antibiotic regimen
prescribed to patients with foot infections
In this analysis we collapsed the extensive array of anti-
biotic regimens into smaller groups on the basis of their
antibacterial spectra. If more than one regimen was
used, we assigned the spectrum based on the first. Only
10 different spectra were used in more than 1.6% of
patients. Table 3 shows how these varied across the
categories of cellulitis as well as across facilities. The
three most frequently used spectra account for 63.7% of
treated patients. Their frequency of use corresponds to
the breadth of their antibacterial spectrum, with the
broadest spectrum being most commonly chosen over-
all. The hierarchy of use for the three most common
spectra is maintained within each type of cellulitis with
two exceptions (Cellulitis Gangrene and Cellulitis Only),
in both of which the deviation reflects a difference less
than two percentage points in the Observed Proportion
column. The table shows that there is substantial varia-
tion in the breadth of the spectrum that is chosen. The
patterns and magnitude of variation are similar to those
described for Table 2.
Discussion
There have been numerous studies of variation in anti-
biotic use in different types of infection [15-22]. The
most common underlying premise has been that varia-
tions in care will reveal deviations from ideal manage-
ment, whether judged by medical outcomes, costs, or
both. Even when there is not agreement about what
constitutes ideal management, there is a presumption
that all treatment strategies are unlikely to be equally
efficacious, so that the presence of substantial variations
reveals the importance of further investigations to deter-
mine which approaches are most cost-effective[23,24].
Evaluation of variation in complex multi-drug
regimens presents methodological challenges. Perhaps
for this reason, most studies of differences in antibiotic
treatment have used strategies that simplify the assess-
ment of variation, such as examining any treatment
versus no treatment,[18] deviation in treatment from
practice guidelines,[17] or differences in antibiotic
regimens when treatment is usually with single drugs, as
is the case with infections like otitis media and respira-
tory tract infections[15,16]. We have not found any that
have evaluated diabetic patients with foot infection, who
are often treated with complex regimens that are not
well-suited to the foregoing methods of analysis.
We decided to carry out such a study, first, because
diabetic foot infections are such an important cause of
hospitalization, amputation, and disability and, second,
because there is no generally accepted standard antibio-
tic regimen, so we expected to find large variations in
antibiotic management. We used data derived from the
computerized medical records of the largest integrated
medical care organization in the country, the Veterans
Health Administration. This gave us the power to evalu-
ate variation in a large variety of antibiotic regimens,
Table 3 Proportion of patients receiving each of the 10 most common antibacterial spectra
Overall Cellulitis and
Gangrene
Cellulitis and
Osteomyelitis
Cellulitis and
Ulcer
Cellulitis Only
(n = 2248) (n = 894) (n = 503) (n = 644) (n = 207)
Observed Proportion (Range*) %
G + St(res) G-Ps An 25.8 (33.9) 26.7 (18.3) 26.2 (43.8) 25.8 (11.0) 20.8 (25.1)
G + St G-Ps An 23.2 (22.0) 28.0 (20.3) 20.9 (19.9) 21.0 (15.8) 15.0 (22.0)
G + St G-Br An 14.7 (45.0) 14.3 (37.3) 13.9 (37.0) 15.2 (18.9) 16.4 (28.6)
G + St(res) G-Ps 7.8 (5.5) 6.8 (5.6) 8.2 (10.1) 9.0 (11.0) 7.2 (8.3)
G + St(res) 6.9 (13.8) 6.2 (6.1) 9.5 (20.7) 5.7 (7.0) 7.7 (13.8)
G + St G- 6.1 (11.7) 4.4 (5.4) 4.4 (18.2) 8.1 (13.4) 11.6 (6.2)
G + St 1.9 (2.2) 1.9 (2.9) 2.0 (8.4) 2.2 (2.5) 1.0 ( - )
G + St(res) G-Br An 1.9 (1.9) 1.0 (9.6) 2.4 (7.5) 1.9 (8.4) 4.3 (11.3)
G + St An 1.8 (5.1) 1.9 (3.5) 1.0 (15.6) 1.7 (5.2) 3.4 (34.5)
G + St(res) G-Br 1.7 (2.7) 1.1 (5.8) 1.4 (12.4) 2.3 (13.1) 2.9 (18.0)
* Statistic uses shrunken hospital rates (see methods)
( - ) No range
Key: G + St = Methicillin sensitive S. aureus
G + St(res) = Methicillin resistant S. aureus
G- = Narrow spectrum Gram negative
G-Br = Broad spectrum Gram negative
G-Ps = Broad spectrum Gram negative including Ps. aeruginosa
An = Specific anaerobic agents (clindamycin or metronidazole)
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across a large number of hospitals, in a large number of
patients. We have focused on patients where antibiotic
choices are most important, namely those with serious
foot infections as defined by hospital treatment for
cellulitis accompanied by gangrene, osteomyelitis,
cutaneous ulcer, or occurring in isolation.
The complex antibiotic regimens often used to treat
diabetic foot infections present methodological issues
that we needed to address before we could begin. First,
we had to take into account that the initial antibiotic
prescribed might not necessarily represent a final deci-
sion about the preferred antibiotic regimen. To address
this we examined what we considered to be a stable
“course” of antibiotics, given singly or in combination,
without change, over a period of at least 5 days. Such a
time frame is a requirement for future studies, which
will not be able to evaluate the outcomes of different
regimens unless they have been given for long enough
to assess clinical response. Second, we recognized that
variation in the choice of antibiotics would be governed,
in part, by the breadth of the anti-bacterial spectrum
desired. Hence, we also examined variation in the anti-
bacterial spectrum of treatment well as variation in the
antibiotics themselves.
We have found very large differences in antibiotic use
across VA facilities. It is evident in the antibiotics that
make up the initial regimen, as well as in the antibacter-
ial spectra of the chosen regimens. The variation may be
partly driven by differences in case mix, but this is unli-
kely, because we did not find substantial differences in
case mix across facilities as judged by the comparative
prevalence of our different categories of cellulitis. It is
probably truly related to foot infections, because the
percentage of patients treated with any antibiotic is
close to 100%, the great majority of treatments are par-
enteral, and the spectrum of antibacterial activity is
broad, all of which are to be expected in the treatment
of these infections[5,25-28]. In addition, there are
expected patterns of treatment related to our different
categories of cellulitis. In particular, patients with the
least complicated infection (Cellulitis-Only) receive
more oral treatment and less often receive 5 or more
continuous days of the same medication.
There is evidence in this study that antibiotic choice is
driven by the existence of differing practice styles across
VA facilities. The variation in antibacterial spectrum
across facilities within each category of infection almost
certainly reflects different views about how broadly to
treat. (The difference between the three most commonly
used regimens, for example, is whether they cover methi-
cillin resistant S. aureus (MRSA), Ps. aeruginosa, or
neither. Each of these organisms is recognized as a cause
of serious foot infections, but they are not so common as
to mandate routine coverage[29].) There is also evidence
for practice variation in the agents chosen to achieve
each spectrum, in that the number of spectra is substan-
tially smaller than the number of regimens. Finally, we
saw in some facilities a particular preference for one or
another of a pair of antibiotics that are very similar in
antibacterial spectrum as well as side effects. Facilities
almost always used one or the other of these pairs, rarely
both. Examples are imipenem versus ertapenem and
ticarcillin/clavulanate versus piperacillin/tazobactam.
Even though there is no general agreement about anti-
biotic choice in the infections we have studied, our find-
ings raise concern about the cost-effectiveness of the
care that is being given. It is unlikely that all regimens
are equally advantageous. For example, there is some
evidence that ampicillin-sulbactam may be more cost-
effective than imipenem[30,31]. There is also a con-
trolled trial that has shown ertapenem to be as effective
in the treatment of diabetic foot infections as piperacil-
lin/tazobactam (one of the most commonly used agents
in our study), and a comparative study of costs esti-
mated ertapenem to be less expensive, primarily because
it had to be administered less frequently [32,33]. We
note, however, that such studies may not be determina-
tive, because other considerations may be more impor-
tant. It may be advisable, for example, to hold a broad-
spectrum antibiotic in reserve if frequent use is known
to generate resistant organisms.
Clearly, further studies are needed to identify which
antibiotic regimens are most cost-effective. This study
has established a number of methodological approaches
that can facilitate the conduct of such investigations
using computerized medical data. These include, 1) a
classification system for diabetic foot infections that can
be applied to computerized medical data; 2) an opera-
tional definition of the initial antibiotic regimen, includ-
ing the requirement to exclude drugs unlikely to be
used for foot infection; 3) a taxonomy for classifying the
spectra of antibacterial agents that has proven to be
useful in evaluating variation in complex antibiotic
regimens, and 4) the benefit of using of shrunken means
to make possible the analysis of antibiotic variation
across large numbers of facilities, each of which may see
only a few patients treated with a given antibiotic regi-
men. These methods set stage for observational studies
of the relationship between different antibiotic regimens,
treatment outcomes, and costs. They are also applicable
to other conditions, such as intra-abdominal infections,
that require empiric treatment with broad-spectrum
regimens that may be achieved using many different
antibiotic combinations.
There are a number of limitations to this study. First,
41% of the patients never met our definition of a stable
antibiotic regimen. This occurred more commonly
among patients with milder infections, which indicates
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that our findings regarding the chosen antibiotic regi-
mens are biased toward patients with greater severity.
This might result in the use of broader spectrum
regimens and therefore reduce observed differences in
treatment across our categories of infection. Second, the
antibiotic regimens that we studied may have been custo-
mized in response to microbiologic data. To explain our
results, however, would require very large differences
across facilities in the prevalence of organisms such as
MRSA and Ps. aeruginosa. In a recent study, each of
these was isolated from less than 5% of cultures, which
makes this possibility very unlikely[29]. Third, ICD-9CM
coding for foot infections is known to contain inaccura-
cies[34]. Despite this, we have found in prior work that
that our classification of foot infections permits meaning-
ful distinctions to be made [9]. Fourth, we do not have
information about comorbidities that might influence
prescribing, such as allergies or renal disease. While this
probably accounts for some variation, it is unlikely that
differences across facilities are great enough to explain
the large variation in antibiotic use that we observed
across hospitals. For example, the most commonly used
regimen that would be affected by penicillin allergy
(piperacillin-tazobactam) has a range of use across hospi-
tals of 23%, while that of the most common regimen that
would be affected by chronic renal disease (piperacillin-
tazobactam plus vancomycin) is 36%. Fifth, the great
majority of patients in our study were male, but it is unli-
kely that gender would have a large effect on antibiotic
choice. Sixth, there is no gold standard for assigning anti-
bacterial spectra to antibiotic regimens and differences of
opinion are likely. Changing the assignment of some of
the regimens, however, would not alter our finding that
there is substantial variation in antibiotic treatment, it
would simply move the source of some of the variation
from one spectrum to another. Last, despite the relatively
large patient population studied, there were small
numbers in many of the facilities and antibiotic groups
studied. While we applied Bayesian shrinkage of the
means to address this problem, the range of true varia-
tion may still have been overestimated.
Conclusions
We have found large variations in the antibiotic regi-
mens used to treat patients with diabetic foot infections.
They appear to reflect facility differences in practice
styles rather than case mix. It is unlikely that these regi-
mens are equally cost-effective. The methods we have
developed can be applied in further studies to examine
both costs and outcomes in order to determine which
regimens should be preferred. They also can be
extended to the evaluation of any condition, infective or
not, that is often treated with a multidrug regimen.
Appendix - ICD-9CM codes
Gangrene
040.0 Gas Gangrene
440.24 Atherosclerosis of the extremities with
gangrene
785.4 Gangrene but only if any one of the following is
also present:
250.7 Diabetes with peripheral circulatory disorders
440.2 Atherosclerosis of native arteries of the
extremities
Any condition classifiable to 440.21, 440.22, and
440.23
Osteomyelitis
730.07 Acute osteomyelitis of ankle and foot
730.17 Chronic osteomyelitis of ankle and foot
730.27 Unspecified osteomyelitis of ankle and foot
730.97 Unspecified infection of bone of ankle and foot
Ulcer
440.23 Atherosclerosis of the extremities with ulceration
707.14 Ulcer of heel and mid foot
707.15 Ulcer of other part of foot
707.1 Ulcer of lower limbs
Cellulitis or abscess of foot
680.7 Carbuncle and furuncle of foot, heel, toe
682.7 Cellulitis and abscess of foot, except toes
Cellulitis or abscess of toe
681.1 Cellulitis and abscess of toe
681.10 Cellulitis, toe nos
Paronychia
681.11 Onychia and paronychia of toe
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